News

BioXcel Therapeutics Progresses with Pivotal Trial Enrollment

BioXcel Therapeutics Progresses with Pivotal Trial Enrollment

BioXcel Therapeutics Reaches 33% Enrollment in SERENITY At-Home Trial

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), based in New Haven, has announced that its SERENITY At-Home clinical trial has successfully achieved 33% enrollment, with 67 patients recruited so far. This significant milestone is part of the pivotal Phase 3 trial assessing the safety of BXCL501, an investigational oral film formulation of dexmedetomidine, designed specifically for the at-home management of agitation associated with bipolar disorders or schizophrenia.

Trial Objectives and Progress

The SERENITY At-Home trial is crucial for the potential expansion of the label for BioXcel's FDA-approved IGALMI® (dexmedetomidine) sublingual film. As noted by Vimal Mehta, Ph.D., the CEO of BioXcel Therapeutics, the trial is being conducted at multiple sites, with a focus on using the lowest approved dose of IGALMI, which stands at 120 mcg. The primary objective of the trial is patient safety, ensuring that the treatment can be administered effectively in a familiar environment.

Overview of the SERENITY At-Home Trial

This double-blinded, placebo-controlled trial aims to enroll a total of 200 patients. Participants will self-administer either BXCL501 or a placebo during episodes of agitation over a 12-week period. The study is gathering safety data meticulously, with a Data Safety Monitoring Board set to evaluate the safety and efficacy throughout the trial.

Significance of the Trial

The necessity for safe and effective treatments for agitation episodes, particularly in the home setting, is profound. Annually, there are around 23 million episodes reported within the U.S. alone, but currently, there are no FDA-approved options catering to this critical need. Therefore, the SERENITY trial represents a vital step toward addressing this treatment gap.

Expectations and Future Goals

While topline data results are anticipated in the latter part of 2025, BioXcel is focused on maintaining the momentum in patient enrollment and completing the trial efficiently. This will help pave the way for a potential supplemental new drug application (sNDA) to expand the use of IGALMI beyond its current approved indications.

About BXCL501

BXCL501 positions itself as a transformative treatment option not only for patients dealing with bipolar disorders and schizophrenia but also for those suffering from agitation due to Alzheimer's dementia. This investigational formulation is expected to redefine treatment protocols, bringing hope to patients and families affected by these conditions.

Contacting BioXcel Therapeutics for More Information

For more details about BioXcel Therapeutics, Inc. or the SERENITY At-Home trial, interested parties can reach out through the company’s contact resources. Direct inquiries can be made via phone at 1-833-201-1088 or via email at medinfo@bioxceltherapeutics.com. Investors and stakeholders can stay informed by visiting bioxceltherapeutics.com.

Frequently Asked Questions

What is the SERENITY At-Home trial about?

The SERENITY At-Home trial assesses the safety of BXCL501 for treating agitation in bipolar disorders and schizophrenia, specifically in home settings.

How many patients are involved in the trial?

The trial aims to enroll a total of 200 patients, and currently, 67 patients have been enrolled.

What is BXCL501?

BXCL501 is a proprietary, orally dissolving film formulation of dexmedetomidine, being investigated for the acute treatment of agitation associated with various psychiatric conditions.

When is the topline data expected?

Topline data from the SERENITY At-Home trial is expected in the latter half of 2025.

How can I learn more about BioXcel Therapeutics?

For more information, visit bioxceltherapeutics.com or contact them directly through the provided communication channels.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading